3.90
-0.3(-7.14%)
Currency In USD
| Previous Close | 4.2 |
| Open | 4.14 |
| Day High | 4.73 |
| Day Low | 3.68 |
| 52-Week High | 4.53 |
| 52-Week Low | 1.33 |
| Volume | 7.02M |
| Average Volume | 529,640 |
| Market Cap | 121.04M |
| PE | -32.5 |
| EPS | -0.12 |
| Moving Average 50 Days | 3.1 |
| Moving Average 200 Days | 2.43 |
| Change | -0.3 |
If you invested $1000 in Fortress Biotech, Inc. (FBIO) 10 years ago, it would be worth $110.17 as of January 14, 2026 at a share price of $3.9. Whereas If you bought $1000 worth of Fortress Biotech, Inc. (FBIO) shares 5 years ago, it would be worth $72.63 as of January 14, 2026 at a share price of $3.9.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States
GlobeNewswire Inc.
Yesterday at 12:45 PM GMT
Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium Cyprium eligible to receive tiered royalties and up to $129 million in aggregate development and sales milestones f
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission
GlobeNewswire Inc.
Dec 15, 2025 1:00 PM GMT
New PDUFA Target Action Date of January 14, 2026 set by FDAMIAMI, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that t
Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics’ Global Phase 3 Trials of Dotinurad for the Treatment of Gout
GlobeNewswire Inc.
Oct 21, 2025 12:30 PM GMT
MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys Therapeutics, Inc. (“Crystalys”), in which Urica maintains